RxSight, Inc. (RXST) Spending and interest coverage
- R&D / revenue · 12 months: Value 30.29%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 25.88%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -3936.64×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 30.29% | Research and development expense / revenue. Period ending 2026-06-30. $36.67M ÷ $121.08M × 100 ≈ 30.29% |
| Stock-based compensation / revenue · 12 months | 25.88% | Share-based compensation / revenue. Period ending 2026-06-30. $31.34M ÷ $121.08M × 100 ≈ 25.88% |
| Interest coverage · 12 months | -3936.64× | Operating income ÷ reported interest expense. $-55.11M ÷ $14.00K ≈ -3936.64× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 36.67M USD | Research and Development Expense |
| Revenue | 121.08M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 31.34M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -55.11M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 14.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.67M | $121.08M | $31.34M | $-55.11M | $14.00K | 30.29% | 25.88% | -3936.64× | Reported |
| 2026-03-31 | $37.65M | $127.48M | $32.42M | $-55.35M | $16.00K | 29.54% | 25.43% | -3459.13× | Reported |
| 2025-12-31 | $38.55M | $134.48M | $31.61M | $-48.19M | $19.00K | 28.67% | 23.51% | -2536.37× | Reported |
| 2025-09-30 | $38.85M | $142.09M | $31.08M | $-45.48M | $19.00K | 27.34% | 21.87% | -2393.79× | Reported |
| 2025-06-30 | $38.63M | $147.06M | $29.52M | $-42.53M | $21.00K | 26.27% | 20.07% | -2025.33× | Reported |
| 2025-03-31 | $36.70M | $148.31M | $27.08M | $-36.86M | $21.00K | 24.75% | 18.26% | -1755.33× | Reported |
| 2024-12-31 | $34.37M | $139.93M | $24.64M | $-36.86M | $21.00K | 24.56% | 17.61% | -1755.14× | Reported |
| 2024-09-30 | $32.50M | $128.29M | $21.78M | $-39.08M | $20.00K | 25.33% | 16.98% | -1954.10× | Reported |
| 2024-06-30 | $30.77M | $115.18M | $19.30M | $-42.37M | $244.00K | 26.71% | 16.75% | -173.64× | Reported |
| 2024-03-31 | $29.87M | $101.10M | $17.15M | $-47.66M | $1.81M | 29.55% | 16.96% | -26.37× | Reported |
| 2023-12-31 | $29.05M | $89.08M | $15.75M | $-50.09M | $3.31M | 32.61% | 17.68% | -15.14× | Reported |
| 2023-09-30 | $28.39M | $76.58M | $14.28M | $-54.22M | $4.75M | 37.07% | 18.65% | -11.40× | Reported |
| 2023-06-30 | $27.68M | $67.00M | $13.09M | $-57.67M | $5.83M | 41.31% | 19.54% | -9.90× | Reported |
| 2023-03-31 | $26.47M | $57.55M | $12.04M | $-59.84M | $5.39M | 45.99% | 20.93% | -11.10× | Reported |
| 2022-12-31 | $25.98M | $49.01M | $11.40M | $-63.32M | $4.95M | 53.02% | 23.26% | -12.80× | Reported |
| 2022-09-30 | $25.22M | $41.34M | $11.35M | $-62.99M | $4.57M | 60.99% | 27.46% | -13.77× | Reported |
| 2022-06-30 | $24.20M | $34.51M | $10.48M | $-60.15M | $4.35M | 70.13% | 30.37% | -13.81× | Reported |
| 2022-03-31 | $24.57M | $28.05M | $8.98M | $-58.23M | $4.04M | 87.61% | 32.03% | -14.40× | Reported |
| 2021-12-31 | $24.50M | $22.59M | $7.58M | $-52.79M | $3.68M | 108.44% | 33.53% | -14.34× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $21.93M | $14.68M | $4.18M | $-35.41M | $510.00K | 149.43% | 28.51% | -69.44× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |